Latamoxef

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318088

CAS#: 64952-97-2 (free acid)

Description: Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins.


Chemical Structure

img
Latamoxef
CAS# 64952-97-2 (free acid)

Theoretical Analysis

MedKoo Cat#: 318088
Name: Latamoxef
CAS#: 64952-97-2 (free acid)
Chemical Formula: C20H20N6O9S
Exact Mass: 520.10
Molecular Weight: 520.473
Elemental Analysis: C, 46.15; H, 3.87; N, 16.15; O, 27.67; S, 6.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 64953-12-4 (sodium)   64952-97-2 (free acid)    

Synonym: Latamoxef, Moxalactam, Lamoxactam, Festamoxin, 6059-S

IUPAC/Chemical Name: (6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

InChi Key: JWCSIUVGFCSJCK-CAVRMKNVSA-N

InChi Code: InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1

SMILES Code: O=C(C(N12)=C(CSC3=NN=NN3C)CO[C@]2([H])[C@](OC)(NC(C(C(O)=O)C4=CC=C(O)C=C4)=O)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 520.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hagiya H, Tasaka K, Sendo T, Otsuka F. Clinical ineffectiveness of latamoxef for Stenotrophomonas maltophilia infection. Infect Drug Resist. 2015 Oct 20;8:353-7. doi: 10.2147/IDR.S90726. eCollection 2015. PubMed PMID: 26527890; PubMed Central PMCID: PMC4621224.

2: Ito A, Tatsumi Y, Wajima T, Nakamura R, Tsuji M. Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation. Jpn J Antibiot. 2014 Apr;67(2):109-22. PubMed PMID: 24956910.

3: Gu HY, Sun DM, Yu AM, Chen HY. [Polarographic behavior of latamoxef sodium and its trace determination]. Yao Xue Xue Bao. 1997 May;32(5):373-6. Chinese. PubMed PMID: 11498875.

4: Chen YC, Hung CC, Lin SF, Chang SC, Hsieh WC. Comparison of flomoxef with latamoxef in the treatment of sepsis and/or Gram-negative bacteremia in adult patients. Int J Antimicrob Agents. 1996 May;7(1):69-74. PubMed PMID: 18611739.

5: Sotto A, Brunschwig C, O'Callaghan D, Ramuz M, Jourdan J. In-vitro evaluation of beta-lactamase inhibition by latamoxef and imipenem. J Antimicrob Chemother. 1996 Apr;37(4):697-701. PubMed PMID: 8722535.

6: Itoh M, Katoh N, Ono Y, Ohshima S, Miyake K. Sequential changes in the prostatic fluid level of latamoxef in patients with acute bacterial prostatitis. Urol Int. 1995;55(2):101-4. PubMed PMID: 8533190.

7: Oturai PS, Holländer NH, Hansen OP, Boas J, Bruun BG, Frimodt-Møller N, Dombernowsky P, Hansen HH. Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours. Eur J Cancer. 1993;29A(9):1274-9. PubMed PMID: 8343267.

8: Katoh N, Ono Y, Ohshima S, Miyake K. Diffusion of cefmenoxime and latamoxef into prostatic fluid in the patients with acute bacterial prostatitis. Urol Int. 1992;48(2):191-4. PubMed PMID: 1585513.

9: Matsui K, Masuda N, Takada M, Kusunoki Y, Fukuoka M. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn J Clin Oncol. 1991 Dec;21(6):428-34. PubMed PMID: 1805048.

10: Bauernfeind A, Schweighart S, Eberlein E, Jungwirth R. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection. 1991;19 Suppl 5:S264-75. PubMed PMID: 1664418.

11: Suzuki Y, Itoh S, Katoh M, Morita M, Fukushi Y, Toyota S, Katoh S, Oikawa K, Orikasa S, Majima K. [Clinical study concerning of latamoxef concentration in the obstructed urinary tract]. Hinyokika Kiyo. 1990 Aug;36(8):897-902. Japanese. PubMed PMID: 2173381.

12: Kouda M, Kumagai I, Kobayashi J, Sugai R, Matsuzaki H. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline]. Jpn J Antibiot. 1990 Apr;43(4):636-58. Japanese. PubMed PMID: 2199689.

13: Kitaura T, Tsukiai S, Arai S, Miyake K, Kimura M, Fukuchi H. Ocular pharmacokinetics of latamoxef and cefaclor in humans. Penetration into aqueous humor. J Pharmacobiodyn. 1989 Jan;12(1):60-6. PubMed PMID: 2724050.

14: Sugawara N, Hisamitsu T, Nakanishi T, Iizuka B, Okuda H, Obata H, Endoh K, Benno Y, Mitsuoka T. Intestinal microflora in cirrhotic patients and their changes after administration of Latamoxef in combination with drug-resistant Bifidobacterium longum. J Gastroenterol Hepatol. 1989;4 Suppl 1:287-8. PubMed PMID: 2519079.

15: Wilson SE. Cephalosporin therapy in intra-abdominal infection: comparative studies of cefotetan, latamoxef and cefoxitin. Chemioterapia. 1988 Aug;7(4):213-7. PubMed PMID: 3180298.

16: Ishida M, Kawamura K, Takekawa H, Takanashi S, Onodera K. [A case of pneumonitis due to latamoxef and tobramycin]. Nihon Kyobu Shikkan Gakkai Zasshi. 1988 Jul;26(7):756-9. Japanese. PubMed PMID: 3241513.

17: Viens P, Maraninchi D, Gaspard MH, Stoppa AM, Blaise D, Miquel M, Mannoni P, Carcassonne Y. [Randomized trial of empirical antibiotic therapy in febrile episodes after bone marrow transplantation. Comparison of an aminoglycoside-beta lactam (tobramycin-ticarcillin) combination with 2 beta-lactam antibiotics (ticarcillin-latamoxef)]. Pathol Biol (Paris). 1988 May;36(5):567-70. French. PubMed PMID: 3043359.

18: Kojima R, Ito M, Suzuki Y. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects. (5). Interaction of tobramycin with latamoxef in vitro. J Pharmacobiodyn. 1988 Jan;11(1):9-17. PubMed PMID: 3385606.

19: Eng RH, Cherubin CE, Pechere JC, Beam TR Jr. Treatment failures of cefotaxime and latamoxef in meningitis caused by Enterobacter and Serratia spp. J Antimicrob Chemother. 1987 Dec;20(6):903-11. PubMed PMID: 3501999.

20: Chimura T, Sato S, Suzuki T, Ito K, Sumiyoshi Y, Kanasugi H, Nakakuki M, Abe Y, Banzai M. [Prophylactic effects of a combined use of a cephem antibiotic, latamoxef, and tobramycin on postoperative infection in obstetrics and gynecology]. Jpn J Antibiot. 1987 Jul;40(7):1253-8. Japanese. PubMed PMID: 3682180.